451 related articles for article (PubMed ID: 29524050)
21. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
Ren PP; Li M; Li TF; Han SY
Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
[TBL] [Abstract][Full Text] [Related]
22. Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives.
Karschnia P; Teske N; Thon N; Subklewe M; Tonn JC; Dietrich J; von Baumgarten L
Neurology; 2021 Aug; 97(5):218-230. PubMed ID: 33986138
[TBL] [Abstract][Full Text] [Related]
23. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
25. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
[TBL] [Abstract][Full Text] [Related]
26. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
Kringel R; Lamszus K; Mohme M
Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
Verma A; Rafiq S
Cancer Treat Res; 2022; 183():161-184. PubMed ID: 35551659
[TBL] [Abstract][Full Text] [Related]
28. Updates On Chimeric Antigen Receptor-Mediated Glioblastoma Immunotherapy.
Mao G; Sampath P; Sengupta S
R I Med J (2013); 2017 Jun; 100(6):39-42. PubMed ID: 28564668
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.
Sengupta S; Mao G; Gokaslan ZS; Sampath P
Cancer Gene Ther; 2017 Mar; 24(3):121-129. PubMed ID: 27767090
[TBL] [Abstract][Full Text] [Related]
30. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
31. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
[No Abstract] [Full Text] [Related]
32. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract][Full Text] [Related]
33. Generation of regulable EGFRvIII targeted chimeric antigen receptor T cells for adoptive cell therapy of glioblastoma.
Zheng Y; Gao N; Fu YL; Zhang BY; Li XL; Gupta P; Wong AJ; Li TF; Han SY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):59-66. PubMed ID: 30409424
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
35. Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells.
Sengupta S; Katz SC; Sengupta S; Sampath P
Cancer Lett; 2018 Oct; 433():131-139. PubMed ID: 29959057
[TBL] [Abstract][Full Text] [Related]
36. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
37. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
Wang C; Yu M; Zhang W
Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
[TBL] [Abstract][Full Text] [Related]
38. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
Shiina S; Ohno M; Ohka F; Kuramitsu S; Yamamichi A; Kato A; Motomura K; Tanahashi K; Yamamoto T; Watanabe R; Ito I; Senga T; Hamaguchi M; Wakabayashi T; Kaneko MK; Kato Y; Chandramohan V; Bigner DD; Natsume A
Cancer Immunol Res; 2016 Mar; 4(3):259-68. PubMed ID: 26822025
[TBL] [Abstract][Full Text] [Related]
39. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
Riccione K; Suryadevara CM; Snyder D; Cui X; Sampson JH; Sanchez-Perez L
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741761
[TBL] [Abstract][Full Text] [Related]
40. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
